Dr. Naumovski has over 30 years of extensive experience in early clinical development of novel oncology drugs specializing in IND filings and proof of concept in clinic. His previous professional experiences include Chief Medical Officer at Genesis Therapeutics and Arch Oncology; Group Medical Director at AbbVie; Senior and Associate roles at Genentech; and Director – Cancer Biology, at Pharmacyclics. Dr. Naumovski led Scientific/Medical diligence teams on deals involving BTK and Bcl-2 inhibitors (Pharmacyclics and Genentech, respectively). Dr. Naumovski holds a MD with specialty training in Pediatric Hematology/Oncology and PhD in Cancer Biology from Stanford University.